Horizon scanning: Afrezza Inhaled Insulin for Diabetes Mellitus
Source: Canadian Agency for Drugs and Technologies in Health (CADTH)
Area: News
This bulletin from the Canadian Agency for Drugs and Technologies in Health (CADTH) discusses investigational inhaled insulin, Afrezza, which consists of Technosphere insulin (TI) inhalation powder and a product-specific breath-activated inhaler. TI cartridges are used with an inhaler one minute before eating for managing type 1 and type 2- diabetes.
Findings from trials include the following:
. TI reduces postprandial glucose and HbA1c levels in type 2 diabetes patients taking oral antidiabetic drugs or concurrent insulin glargine (IG) compared with placebo.
. Patients with poorly controlled type 2 diabetes taking TI showed comparable reductions in postprandial glucose and HbA1c compared with biaspart insulin (BI) recipients.
. No significant differences in hypoglycaemia, cough, pulmonary function, or weight were reported between patients receiving TI compared with placebo.
. Patients taking TI ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Cough | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Health | Insulin | Lantus | PET Scan